The FDA cleared the first prescription digital therapeutic app for major depressive disorder.
The app, called Rejoyn, was developed by Otsuka America Pharmaceutical for patients 22 and older who are on antidepressant medication, according to an April 1 company news release. The app is a six-week treatment program to enhance cognitive control of emotion through combined cognitive emotional training exercise and brief therapeutic lessons. It is intended to reduce depression symptoms.
The app is meant to be used alongside medication and talk therapy and requires a prescription by a healthcare professional, the release said.